Abstract | OBJECTIVES:
Butyrophenones have been reported to provide effective migraine relief in the emergency department (ED). We conducted a systematic review of the evidence for their use in the ED. DATA SOURCE: We searched the Cochrane, Medline, Embase, and CINAHL databases. STUDY SELECTION: Included studies were randomized trials of a parenteral butyrophenone ( droperidol, haloperidol) versus placebo or a comparator in migraine or benign headache with results available in English. Study quality was determined using the Jadad score. Six articles were included. DATA EXTRACTION: Primary outcomes were subjective or objective headache relief (>50% improvement in visual analogue scale scores). Secondary outcomes included side effects. We reported pooled odds ratios ( ORs) with their 95% confidence intervals (CIs) for subjective or objective headache relief for butyrophenones versus placebo or comparator agents. DATA SYNTHESIS: CONCLUSIONS:
|
Authors | Lim Beng Leong, Anne-Maree Kelly |
Journal | CJEM
(CJEM)
Vol. 13
Issue 2
Pg. 96-104
(Mar 2011)
ISSN: 1481-8043 [Electronic] England |
PMID | 21435315
(Publication Type: Journal Article, Review, Systematic Review)
|
Chemical References |
- Butyrophenones
- Haloperidol
- Droperidol
|
Topics |
- Butyrophenones
(administration & dosage, therapeutic use)
- Droperidol
(therapeutic use)
- Emergency Service, Hospital
- Haloperidol
(therapeutic use)
- Headache
(drug therapy)
- Humans
- Migraine Disorders
(drug therapy)
- Randomized Controlled Trials as Topic
- Treatment Outcome
|